Host intestinal mucosa and immune pathways

The host intestinal mucosa and immune pathways encompass the integrated network of physical barriers and immune components that maintain gastrointestinal homeostasis. This system includes the intestinal epithelial layer, which provides a selective barrier, and the gut-associated lymphoid tissue (GALT), which coordinates immune responses to the diverse microbiota and dietary antigens (Mowat & Agace, 2014). These pathways involve complex signaling through cytokines (e.g., TNF-alpha, IL-23), chemokines, and cell-adhesion molecules that regulate the recruitment and activation of immune cells like T cells and macrophages (Neurath, 2014). Dysregulation of these pathways is central to the pathogenesis of inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, where an aberrant immune response leads to chronic mucosal inflammation and tissue damage (Xavier & Podolsky, 2007). Therapeutic strategies targeting this system aim to restore balance by inhibiting pro-inflammatory mediators or blocking the trafficking of inflammatory cells into the gut mucosa (Danese et al., 2015). Common pharmacological interventions include monoclonal antibodies against TNF-alpha or integrins, as well as small molecule inhibitors of Janus kinases (JAKs) and modulators of microRNA expression.

Other names

Intestinal mucosal immune systemGut-associated lymphoid tissueGALTGut-immune axisMucosal immune systemImmunity, Mucosal

Drugs targeting these pathways typically function by neutralizing pro-inflammatory cytokines (e.g., TNF-alpha, IL-12/23), inhibiting leukocyte trafficking to the intestinal mucosa (e.g., alpha4beta7 integrin antagonism), or modulating intracellular signaling (e.g., JAK inhibition or miR-124 upregulation) to reduce inflammation and promote mucosal healing.